glp 1 neurotransmitter From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics Acute activation of GLP-1-expressing neurons

GLP-1 drugs have been approved for the treatment of diabetes and obesity, meaning that the FDA has determined that for people with these disorders, the benefits of taking the drug outweigh the potential risks

If you forget a dose, it can still be taken if your next dose is more than two days away

Serious but rare risks include hypoglycemia (low blood sugar), acute pancreatitis (severe, persistent abdominal pain often with vomiting), acute gallbladder disease (sudden right-upper abdominal pain that may radiate to the shoulder), non-arteritic anterior ischemic optic neuropathy (sudden, potentially permanent vision loss), mood changes, and severe allergic reactions with breathing difficulty or swelling of the lips, tongue, or throat

doi:10.1210/clinem/dgad463 Lin S, Deng Y, Huang J, et al

This medications safety profile has not been studied in patients under the age of 18, pregnant and lactating people, or those with normal BMIs. At the time of publishing, the FDA has only approved three GLP-1 agonists for weight loss: Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide)

Receptors upregulate and downregulate in rhythm with expected drug levels